Background: PCR-based techniques for the diagnosis of community- acquired severe lower respiratory tract infections are becoming the standard of care. However, their relative ability to identify either atypical bacteria or viruses that cause LRTI from clinical samples from various sources is yet to be determined.
Objectives And Study Design: The aim of our study was to compare the diagnostic yield of nasopharyngeal aspirates with that of pulmonary samples for the etiological diagnosis of severe acute lower respiratory tract infections by multiplex PCR. Patients were adults with community-acquired pneumonia or acute exacerbation of chronic obstructive pulmonary disease.
Results: We obtained concordant results for 81 (79%) of the 103 pairs of samples. In 14 of the 22 discordant results, more pathogens were evidenced in the lower respiratory tract samples.
Conclusions: Pulmonary samples had a similar diagnostic sensitivity for virus detection by multiplex PCR as nasopharyngeal aspirates. In contrast, in our study, the diagnostic efficacy of pulmonary samples for Legionella pneumophila over simple aspirates was clearly superior.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185397 | PMC |
http://dx.doi.org/10.1016/j.jcv.2018.08.001 | DOI Listing |
Vet Res
January 2025
Department of Microbiology and Cell Biology, Montana State University, Bozeman, MT, USA.
M. ovipneumoniae is a respiratory pathogen that can cause mild to moderate pneumonia and reduced productivity in domestic lambs. However, studies on both natural and experimental M.
View Article and Find Full Text PDFDiscov Oncol
January 2025
Spinal Surgery Department, the Fourth People's Hospital of Jinan, No.50 Normal Road, Tianqiao District, Jinan, 250031, Shandong, China.
Background: It is known that genomic instability contributes to cancer development. Mitotically associated long non-coding RNA (MANCR) has been reported to promote genomic stability, suggesting its involvement in cancers. Therefore, this study was conducted to investigate the role of MANCR in non-small cell lung cancer (NSCLC).
View Article and Find Full Text PDFDiscov Oncol
January 2025
Respiratory Department, Zhejiang Jinhua Guangfu Cancer Hospital, Jinhua, 310053, Zhejiang, China.
Background: Plasma proteins contribute to the identification, diagnosis, and prognosis of human illnesses, which may be conducive to understanding the molecular mechanism and diagnosis of Lung adenocarcinoma (LUAD).
Methods: We collected plasma samples from 28 healthy individuals (H) and 56 LUAD patients and analyzed them using LC-MS/MS-based proteomics to determine differential expression plasma proteins (DEPPs). Then, the DEPPs were subjected to a two-sample Mendelian randomization (MR) study based on an "Inverse variance weighted (IVW)" approach to investigate the causal relationships between DEPPs and LUAD.
Radiol Phys Technol
January 2025
Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.
Lung function assessment is essential for determining the optimal treatment strategy for radiation therapy in patients with lung tumors. This study aimed to develop radiomics and dosiomics approaches to estimate pulmonary function test (PFT) results in post-stereotactic body radiation therapy (SBRT). Sixty-four patients with lung tumors who underwent SBRT were included.
View Article and Find Full Text PDFNat Med
January 2025
Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Circulating tumor DNA (ctDNA) detection can predict clinical risk in early-stage tumors. However, clinical applications are constrained by the sensitivity of clinically validated ctDNA detection approaches. NeXT Personal is a whole-genome-based, tumor-informed platform that has been analytically validated for ultrasensitive ctDNA detection at 1-3 ppm of ctDNA with 99.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!